• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Omega Funds Closes Oversubscribed $647 Million Fund VIII to Invest in Transformative Life Science Companies

    7/21/25 7:00:00 AM ET
    $BBNX
    $BCAX
    $KMTS
    $MORF
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BBNX alert in real time by email

    Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs.

    Since its inception in 2004, Omega Funds has raised $2.5 billion to invest in exceptional entrepreneurs developing innovative products across multiple therapeutic areas, including oncology, immunology, rare diseases, medical devices, and precision medicine.

    Fund VIII builds upon the prior success of Omega Funds, resulting in 52 commercialized products being brought to market by Omega portfolio companies. The firm's investments have resulted in 50 exits via M&A, and 47 public listings. Omega's recent M&A exits and IPOs include SoniVie (acquired by Boston Scientific), Scorpion Therapeutics (acquired by Eli Lilly), Kestra Medical Technologies (NASDAQ:KMTS), Beta Bionics (NASDAQ:BBNX), Upstream Bio (NASDAQ:UPB), Bicara Therapeutics (NASDAQ:BCAX), Morphic Therapeutic (NASDAQ:MORF, acquired by Eli Lilly)), EyeBio (acquired by Merck), Imago BioSciences (NASDAQ:IMGO, acquired by Merck)), Amunix Pharmaceuticals (acquired by Sanofi), and Chord Therapeutics (acquired by Merck KGaA).

    "We are very grateful to our investors for the support and trust, particularly given this exceptionally challenging fundraising environment. By exceeding its target size, Fund VIII is a recognition of our investment strategy and track record of consistent exits across market cycles," said Otello Stampacchia, Founder and Managing Director of Omega Funds. "We appreciate the partnership from both our longstanding and new limited partners."

    "As with prior funds, Fund VIII will support management teams in the U.S. and Europe through company creation, early venture rounds, and later-stage financings," said Francesco Draetta, Managing Director of Omega Funds. "We believe our broad investment strategy is well-positioned for navigating this period of macro and policy uncertainty. We look forward to contributing our capital, expertise, and network connectivity in partnering with entrepreneurs, founders, co-investors, and the broader community to transform the standards of care for severe diseases."

    About Omega Funds

    Founded in 2004, Omega Funds is a leading international venture capital firm that creates and invests in life sciences companies that target our world's most urgent medical needs. Omega focuses on identifying and supporting companies through value inflection points across the full arc of innovation, from company formation through clinical milestones and commercial adoption. Omega Funds' portfolio companies have brought 52 commercialized products to market in multiple therapeutic areas, including oncology, rare diseases, precision medicine, medical devices, and others. Please visit www.omegafunds.com for additional information.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250721567050/en/

    Media Contact:

    Michael Beyer

    Harbinger Group

    Tel: 312-961-2502

    E-mail: [email protected]

    Omega Contact:

    Sean Cumiskey

    Head of Investor Relations

    Tel: 617-721-4388

    E-mail: [email protected]

    Get the next $BBNX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BBNX
    $BCAX
    $KMTS
    $MORF

    CompanyDatePrice TargetRatingAnalyst
    Bicara Therapeutics Inc.
    $BCAX
    8/19/2025$36.00Overweight
    Piper Sandler
    Beta Bionics Inc.
    $BBNX
    6/16/2025$26.00Buy
    Truist
    Beta Bionics Inc.
    $BBNX
    6/12/2025$30.00Buy
    Lake Street
    Beta Bionics Inc.
    $BBNX
    5/30/2025$16.00Neutral
    Goldman
    Beta Bionics Inc.
    $BBNX
    5/30/2025$20.00Outperform
    Wolfe Research
    Bicara Therapeutics Inc.
    $BCAX
    5/23/2025$8.00Underweight → Equal Weight
    Wells Fargo
    Bicara Therapeutics Inc.
    $BCAX
    4/17/2025$8.00Underweight
    Wells Fargo
    Kestra Medical Technologies Ltd.
    $KMTS
    3/31/2025$30.00Buy
    BofA Securities
    More analyst ratings

    $BBNX
    $BCAX
    $KMTS
    $MORF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cohen Raymond W bought $289,000 worth of shares (17,000 units at $17.00) and was granted 10,909 shares, increasing direct ownership by 215% to 40,903 units (SEC Form 4)

    4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

    9/8/25 5:38:22 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Chief Product Officer Mensinger Mike bought $566,950 worth of shares (33,350 units at $17.00), converted options into 15,107 shares, exercised 10,575 in-the-money shares at a strike of $0.02 and sold $221 worth of shares (13 units at $17.00) (SEC Form 4)

    4 - Beta Bionics, Inc. (0001674632) (Issuer)

    2/3/25 8:30:15 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Large owner Wellington Hadley Harbor Aggregator Iv, L.P. converted options into 2,901,599 shares and bought $17,000,000 worth of shares (1,000,000 units at $17.00) (SEC Form 4)

    4 - Beta Bionics, Inc. (0001674632) (Issuer)

    2/3/25 4:49:52 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    $BBNX
    $BCAX
    $KMTS
    $MORF
    SEC Filings

    View All

    Kestra Medical Technologies Ltd. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Filer)

    9/4/25 4:48:03 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by Beta Bionics Inc.

    144 - Beta Bionics, Inc. (0001674632) (Subject)

    9/4/25 4:33:15 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Upstream Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Upstream Bio, Inc. (0002022626) (Filer)

    9/2/25 8:38:15 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBNX
    $BCAX
    $KMTS
    $MORF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

    WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15, 2025 at 10:30 a.m. ET. A live webcast of the fireside chat will be available under the Events tab on the Investors section of the Company's website. A replay will be posted on the Company's website following the presentation. About Upstream BioUpstream Bio is a clinical-stage biotechno

    9/9/25 7:00:00 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

    – In this 24-week study, VIBRANT met its primary endpoint, with verekitug dosed every 12 weeks leading to a statistically significant and clinically meaningful reduction from baseline in placebo-adjusted endoscopic nasal polyp score (NPS) of -1.8 (p<0.0001) – – Significant and clinically meaningful improvements were observed in key secondary endpoints, including -0.8 (p=0.0003) reduction in nasal congestion score and 76% (p=0.03) reduction in need for surgery or systemic corticosteroids – – No serious adverse events (SAEs) observed; generally well tolerated safety profile consistent with previous studies – – Observed clinical effect on endoscopic NPS in this Phase 2 trial suggests verekit

    9/2/25 6:00:00 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

    WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced it will report top-line data from the Phase 2 VIBRANT trial of verekitug, the only known clinical-stage monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP), on Tuesday, September 2, 2025. The VIBRANT trial (NCT06164704) was a Phase 2 global, randomized, placebo-controlled, parallel group clinical trial designed to assess the efficacy and safety of verekitug in adults with CRSwNP. Participants received either 100 mg of verekitug or pl

    9/1/25 5:00:00 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBNX
    $BCAX
    $KMTS
    $MORF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Bicara Therapeutics with a new price target

    Piper Sandler initiated coverage of Bicara Therapeutics with a rating of Overweight and set a new price target of $36.00

    8/19/25 8:33:19 AM ET
    $BCAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Beta Bionics with a new price target

    Truist initiated coverage of Beta Bionics with a rating of Buy and set a new price target of $26.00

    6/16/25 7:46:03 AM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Lake Street initiated coverage on Beta Bionics with a new price target

    Lake Street initiated coverage of Beta Bionics with a rating of Buy and set a new price target of $30.00

    6/12/25 8:09:02 AM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    $BBNX
    $BCAX
    $KMTS
    $MORF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Feider Stephen exercised 9,900 shares at a strike of $5.10 and sold $209,151 worth of shares (9,900 units at $21.13) (SEC Form 4)

    4 - Beta Bionics, Inc. (0001674632) (Issuer)

    9/9/25 4:12:26 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Hopman Mark sold $370,837 worth of shares (18,229 units at $20.34) and exercised 16,160 shares at a strike of $5.10, decreasing direct ownership by 6% to 31,215 units (SEC Form 4)

    4 - Beta Bionics, Inc. (0001674632) (Issuer)

    9/8/25 6:15:07 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Feider Stephen exercised 100 shares at a strike of $5.10 and sold $2,100 worth of shares (100 units at $21.00) (SEC Form 4)

    4 - Beta Bionics, Inc. (0001674632) (Issuer)

    9/8/25 6:15:04 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    $BBNX
    $BCAX
    $KMTS
    $MORF
    Leadership Updates

    Live Leadership Updates

    View All

    InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

    MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Raymond W. Cohen to its Board of Directors. Mr. Cohen has over 40 years of leadership experience in medical technology with a successful track record of scaling commercial operations and creating shareholder value through market leadership and successful exit transactions. "We are thrilled to welcome Ray to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "We expect to benefit greatly from his vast insights and experience. His

    7/31/25 8:31:00 AM ET
    $KMTS
    $NSPR
    Medical/Dental Instruments
    Health Care

    Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board

    HOUSTON, July 31, 2025 /PRNewswire/ -- The Rice Biotech Launch Pad, a Houston-based accelerator focused on expediting the translation of Rice University's health and medical technology discoveries into cures, announced today the appointment of Carolyn Ng to its external advisory board. A current business unit partner at TPG Life Sciences Innovations, Ng brings expertise in biotech and company building with a track record of guiding early to midstage companies across a wide range of therapeutic areas. "Carolyn's deep understanding of translational science, combined with her passion for fostering high-impact ventures, makes her an ideal addition to the board," said Omid Veiseh, professor of b

    7/31/25 7:00:00 AM ET
    $BCAX
    $BCYC
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Archimedes Vascular Announces Close of Series A Financing led by Sherpa Healthcare Partners and Appoints Raymond W. Cohen as Chairman of its Board of Directors

    BIRMINGHAM, Ala. and BEIJING, June 23, 2025 /PRNewswire/ -- Archimedes Vascular, Inc., a pre-clinical stage medical device company developing an implant for the treatment of severe hypertension announced a $2.2 million Series A financing led by Sherpa Healthcare Partners. In conjunction with the financing, also announced the appointment of veteran medical device executive, Raymond W. Cohen to serve as chairman of its board of directors. "We are grateful to Sherpa and Ray for recognizing the potential of this exciting project and providing the funding to facilitate execution of

    6/23/25 9:00:00 AM ET
    $BSX
    $KMTS
    Medical/Dental Instruments
    Health Care

    $BBNX
    $BCAX
    $KMTS
    $MORF
    Financials

    Live finance-specific insights

    View All

    Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

    – In this 24-week study, VIBRANT met its primary endpoint, with verekitug dosed every 12 weeks leading to a statistically significant and clinically meaningful reduction from baseline in placebo-adjusted endoscopic nasal polyp score (NPS) of -1.8 (p<0.0001) – – Significant and clinically meaningful improvements were observed in key secondary endpoints, including -0.8 (p=0.0003) reduction in nasal congestion score and 76% (p=0.03) reduction in need for surgery or systemic corticosteroids – – No serious adverse events (SAEs) observed; generally well tolerated safety profile consistent with previous studies – – Observed clinical effect on endoscopic NPS in this Phase 2 trial suggests verekit

    9/2/25 6:00:00 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

    WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced it will report top-line data from the Phase 2 VIBRANT trial of verekitug, the only known clinical-stage monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP), on Tuesday, September 2, 2025. The VIBRANT trial (NCT06164704) was a Phase 2 global, randomized, placebo-controlled, parallel group clinical trial designed to assess the efficacy and safety of verekitug in adults with CRSwNP. Participants received either 100 mg of verekitug or pl

    9/1/25 5:00:00 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kestra Medical Technologies, Ltd. to Report First Quarter Fiscal 2026 Financial Results

    KIRKLAND, Wash., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced that it will report first quarter fiscal 2026 financial results on Thursday, September 11. Management will host a corresponding conference call at 4:30 p.m. Eastern Time. A live and archived webcast of the conference call will be available in the "Events" section of the investor relations website. Participants are encouraged to register on the website at least 10 minutes prior to the start of the conference call. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital h

    8/28/25 8:00:00 AM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    $BBNX
    $BCAX
    $KMTS
    $MORF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Upstream Bio Inc.

    SC 13G - Upstream Bio, Inc. (0002022626) (Subject)

    11/7/24 9:24:55 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Upstream Bio Inc.

    SC 13D - Upstream Bio, Inc. (0002022626) (Subject)

    10/22/24 4:06:27 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Upstream Bio Inc.

    SC 13G - Upstream Bio, Inc. (0002022626) (Subject)

    10/18/24 6:10:56 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care